Deforolimus (AP-23573, MK-8669, Ridaforolimus) potent, selective mTOR inhibitor with IC50 of 0.2 nM in HT-1080 cell line.
Deforolimus displays significant antiproliferative activity a broad panel of cell lines with EC50 of 0.2-2.3 nM.
Deforolimus potently and selectively inhibits VEGF production in a dose-dependent manner.
Deforolimus exerts significant antitumor effects in mice bearing PC-3 (prostate), HCT-116 (colon), MCF7 (breast), PANC-1 (pancreas) or A549 (lung) xenografts.
Physicochemical Properties
M.Wt
990.2061
Formula
C53H84NO14P
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
DMSO: ≥ 44 mg/mL
Chemical Name/SMILES
Rapamycin, 42-(dimethylphosphinate) (9CI)
References
1. Rivera VM, et al. Mol Cancer Ther. 2011 Jun;10(6):1059-71.
2. Legrier ME, et al. Cancer Res. 2007 Dec 1;67(23):11300-8.
3. Becker MA, et al. BMC Cancer. 2016 Oct 20;16(1):814.
